ABRAM Therapeutics Limited

Abram Therapeutics is developing ABarginase, a biopharmaceutical solution for metabolic diseases, including obesity, type 2 diabetes and non-alcoholic fatty liver disease (NAFLD). Obesity and related metabolic disorders are causing a global health crisis, with 1.9 billion adults classified as overweight, accounting for 39% of global adult population; and 650 million adults diagnosed as obese, equivalent to 13% of global adult population. In 2019, 463 million adults, meaning one in every 11 persons, have diabetes, and the number is expected to rise 25% by 2030 and 51% by 2045. Currently approved weight-loss and diabetes medications have various disadvantages and side effects. Till now, there is only one FDAapproved drug for NAFLD. There is a high unmet need for safe and effective therapeutics. ABarginase can simultaneously treat and prevent multiple metabolic diseases, with the following advantages: (1) longacting; (2) cost-effective production; and (3) no drug resistance and safe for long-term use.

Prof. SHUM Sau Wun Alisa

Dr. WONG Piu Bill